LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States
23.2.2021 01:33:00 EET | Business Wire | Press release
LG Chem Life Sciences (“LG Chem”) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.
LG Chem licensed LG00303174 (TT-01025) from TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China. LG Chem had entered into an exclusive license agreement with TransThera in August 2020 to research, develop, manufacture, and commercialize LG00303174 in the world except China and Japan.
LG00303174 is a potential best-in-class novel SSAO/VAP-1 inhibitor, currently being developed for the treatment of chronic inflammatory diseases, including non-alcoholic steatohepatitis (NASH). The phase 1 study is currently being conducted within the U.S. and approximately 64 subjects are expected to be enrolled.
“The commencement of this study is a significant landmark for LG Chem as we are determined to address the clear unmet needs of those with metabolic disease,” said Adam Benson, Director of Clinical Development of LG Chem Life Sciences Innovation Center in Cambridge, MA. “NASH to this day remains an elusive target. We feel strongly that LG00303174 has shown, in pre-clinical models, to have a strong safety profile, and as an oral therapy, has the potential to address a clear need in a disease that is becoming increasingly burdensome to our healthcare system.”
Dr. Frank Wu, CEO of TransThera, commented: “We congratulate LG Chem team on the rapid implementation of FIH trial in the United States, which marks a key milestone for this collaboration program.”
According to Dr. Jeewoong Son, President of LG Chem Life Sciences in Seoul, Korea, the fast and efficient implementation of this phase 1 study “is a testament to our clinical development capabilities of the LG Chem Life Sciences Innovation Center in Cambridge as a center of excellence to enrich and forward our development pipeline.”
About LG Chem Life Sciences
LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.
LG Chem Life Sciences Innovation Center: innovation.lgchem.com
About TransThera Biosciences
TransThera Biosciences is a clinical-stage biotechnology company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via internal research platform and open innovation. TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases. For more information, please visit www.transtherabio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005934/en/
Contact information
Media (Jiin Chung): media.cbl@lgchem.com
General Inquiries: contact.cbl@lgchem.com
Partners: partners.cbl@lgchem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC Momentum Extends Award-Winning UX Track Record with Two UX Design Awards Honors3.9.2026 15:18:00 EEST | Press release
HTEC Momentum, the product and design practice within HTEC Group, has earned honors at the UX Design Awards 2026 for its work with Zingtree and the National Society Daughters of the American Revolution (DAR). Presented by the International Design Center Berlin (IDZ), the global competition celebrates excellence in user experience design across industries, with the 2026 shortlist including 195 projects across 46 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903181166/en/ HTEC Momentum, the product and design practice within HTEC Group, has earned honors at the UX Design Awards 2026 for its work with Zingtree and the National Society Daughters of the American Revolution (DAR). Presented by the International Design Center Berlin (IDZ), the global competition celebrates excellence in user experience design across industries, with the 2026 shortlist including 195 projects across 46 countries. Honored in the product
Former SADA Executive Lusine Yeghiazaryan Joins Picsart as CFO to Drive AI-Native Video Growth Strategy3.9.2026 15:00:00 EEST | Press release
Picsart, the AI media production and distribution platform, where 100M+ creators and businesses worldwide make, market and monetize content, today announced the appointment of Lusine Yeghiazaryan as Chief Financial Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903569581/en/ Picsart, the AI media production and distribution platform, where 100M+ creators and businesses worldwide make, market and monetize content, today announced the appointment of Lusine Yeghiazaryan as Chief Financial Officer. Yeghiazaryan joins Picsart at a pivotal chapter in its evolution, as the company expands beyond its roots as a leading creative platform to build a video-first, AI-powered production ecosystem. Already in motion, Picsart users created over 1.1B AI videos and images since launch, with YTD AI usage up 270% year over year - underscoring the company’s accelerating push to capture a larger share of the fast-growing AI content m
NetApp and AWS Accelerate Storage Migrations with AWS Transform3.9.2026 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Amazon Web Services (AWS) today announced that AWS Transform now supports Amazon FSx for NetApp ONTAP, making it even easier for enterprises to move applications and data to AWS. AWS Transform is an agentic AI service that automates the discovery, planning, and migration of workloads to the cloud. Now generally available, customers can use AWS Transform to migrate attached storage from their on-premises and cloud estates directly to Amazon FSx for ONTAP. “Cloud migration projects often take longer and cost more than expected because customers have to move applications, servers, networking, and storage separately,” said Pravjit Tiwana, Senior Vice President and General Manager, Cloud Storage and Services at NetApp. “With AWS Transform and Amazon FSx for NetApp ONTAP, customers can simplify that process, reduce migration risk, and move to AWS faster without changing how their applications operate.” Amazon FSx for Ne
Hitachi Expands HMAX to Accelerate the Deployment of Physical AI3.9.2026 15:00:00 EEST | Press release
Hitachi, Ltd. ("Hitachi") today announced the expansion of HMAX by Hitachi ("HMAX")*, a next-generation suite of solutions that brings the power of AI to social infrastructure. The HMAX portfolio consists of Domain-Specific Solutions tailored to industries and business operations, as well as a set of foundry solutions that span across domains. As part of this expansion, HMAX Data Center has been added as a Domain-Specific Solution for data center operators. Additionally, HMAX Cyber, HMAX Data Fabric, and HMAX AI Operations are being introduced as foundry solutions that support not only Physical AI initiatives within HMAX but also integrate and support enterprises' existing systems across different domains and environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903046122/en/ HMAX Solutions Portfolio Overview Today, social infrastructure operators face growing challenges as the number and complexity of facilities a
MultiBank Group Named Most Regulated Global Financial Derivatives Institution.3.9.2026 14:47:00 EEST | Press release
MultiBank Group has won the Most Regulated Global Financial Derivatives Institution Award at Money Expo India 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903046526/en/ MultiBank Group has won the Most Regulated Global Financial Derivatives Institution Award at Money Expo India 2026. The award highlights MultiBank Group’s strong global regulatory framework as it holds more than 18 regulatory licences across five continents, including the Australian Securities and Investments Commission (ASIC), the German Federal Financial Supervisory Authority (BaFin), the Cyprus Securities and Exchange Commission (CySEC), the UAE’s Capital Market Authority (CMA), reflecting its longstanding commitment to governance, compliance and transparency. The latest recognition adds to MultiBank Group’s growing award portfolio of more than 80 international industry awards, spanning areas including financial services, trading technology, reg
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom